1.南京中医药大学 附属无锡医院,江苏 无锡 214071
2.南京中医药大学,南京 210023
张卓珺,博士,在站博士后,从事中医药防治心血管疾病的临床研究,E-mail:zzj566556@163.com
谈晓东,博士,副主任中医师,从事中医药防治心血管疾病的临床研究,E-mail:wxzy067@njucm.edu.cn
陆曙,博士,教授,从事中医药防治心血管疾病的临床研究,Tel:0510-88859999,E-mail:953023765@qq.com; *
收稿:2025-08-18,
修回:2025-11-21,
录用:2025-12-23,
网络首发:2025-12-25,
纸质出版:2026-06-05
移动端阅览
张卓珺,沈丽娟,蓝弘毅等.参芪养心汤治疗缺血性心肌病患者的临床疗效及对血清H2S、Ca2+的影响[J].中国实验方剂学杂志,2026,32(11):210-217.
ZHANG Zhuojun,SHEN Lijuan,LAN Hongyi,et al.Clinical Efficacy of Shenqi Yangxin Decoction in Treatment of Patients with Ischemic Cardiomyopathy and Its Effect on Serum H2S and Ca2+[J].Chinese Journal of Experimental Traditional Medical Formulae,2026,32(11):210-217.
张卓珺,沈丽娟,蓝弘毅等.参芪养心汤治疗缺血性心肌病患者的临床疗效及对血清H2S、Ca2+的影响[J].中国实验方剂学杂志,2026,32(11):210-217. DOI: 10.13422/j.cnki.syfjx.20260692.
ZHANG Zhuojun,SHEN Lijuan,LAN Hongyi,et al.Clinical Efficacy of Shenqi Yangxin Decoction in Treatment of Patients with Ischemic Cardiomyopathy and Its Effect on Serum H2S and Ca2+[J].Chinese Journal of Experimental Traditional Medical Formulae,2026,32(11):210-217. DOI: 10.13422/j.cnki.syfjx.20260692.
目的
2
评价名中医临床验方参芪养心汤治疗缺血性心肌病(ICM)气阴两虚血瘀证患者的临床疗效和对血清硫化氢(H
2
S)、钙离子(Ca
2+
)的影响。
方法
2
将64例符合纳入标准的ICM气阴两虚血瘀证患者应用随机数表法分为对照组(32例)和观察组(32例)。所有患者均接受西医常规治疗,观察组在此基础上加用参芪养心汤治疗。比较两组患者治疗前后的中医证候积分、明尼苏达心衰生活质量评分、左心室射血分数(LVEF)、N末端B型利钠肽前体(NT-proBNP)、6 min步行试验(6MWT)、纽约心脏病协会(NYHA)心功能分级、血清H
2
S和Ca
2+
水平。
结果
2
研究过程中对照组和观察组各脱落2例,最终对照组和观察组各纳入患者30例。两组患者在年龄、性别、冠心病病程、基础疾病、实验室检查方面差异无统计学意义,资料具有可比性。与本组治疗前比较,治疗后观察组和对照组的中医证候积分、明尼苏达心衰生活质量评分、NT-proBNP均显著下降(
P
<
0.01),LVEF、6MWT、H
2
S均显著升高(
P
<
0.01),血清Ca
2+
明显升高(
P
<
0.05)。与对照组治疗后比较,观察组明尼苏达心衰生活质量评分、NT-proBNP明显下降(
P
<
0.05),中医证候积分显著下降(
P
<
0.01),LVEF、6MWT、血清Ca
2+
明显升高(
P
<
0.05),H
2
S显著升高(
P
<
0.01),观察组NYHA心功能分级改善程度高于对照组,但差异无统计学意义。
结论
2
参芪养心汤治疗ICM气阴两虚血瘀证患者疗效显著,能明显改善心功能,提高生活质量,其疗效可能与调节血清H
2
S和Ca
2+
水平有关。
Objective
2
To evaluate the clinical efficacy of Shenqi Yangxin decoction in the treatment of ischemic cardiomyopathy (ICM) with Qi and Yin deficiency and blood stasis syndrome and its effect on serum hydrogen sulfide (H
2
S) and calcium ion (Ca
2+
).
Methods
2
A total of 64 ICM patients with Qi and Yin deficiency and blood stasis syndrome who met the inclusion criteria were randomly divided into a control group (
n
=32) and a treatment group (
n
=32). All patients received conventional Western medicine treatment. The treatment group was additionally given Shenqi Yangxin decoction. The TCM syndrome score, Minnesota Living with Heart Failure Questionnaire (MLHFQ) score, left ventricular ejection fraction (LVEF), N-terminal pro-B-type natriuretic peptide (NT-proBNP), 6-minute walk test (6MWT), New York Heart Association (NYHA) cardiac function classification, and serum H
2
S and Ca
2+
levels were compared between the two groups pre- and post-treatment.
Results
2
Two cases dropped out from each group during the study. Finally, 30 patients in each group were included in the analysis. There were no significant differences in age, gender, course of coronary heart disease, underlying diseases, and laboratory tests between the two groups. Compared with baseline, the TCM syndrome score, MLHFQ score, and NT-proBNP in both treatment group and control group decreased significantly (
P
<
0.01), LVEF, 6MWT, and H
2
S increased significantly (
P
<
0.01), and serum Ca
2+
increased (
P
<
0.05). Compared with the control group after treatment, the MLHFQ score and NT-proBNP in the treatment group decreased (
P
<
0.05), the TCM syndrome score decreased significantly (
P
<
0.01), LVEF, 6MWT, and serum Ca
2+
increased (
P
<
0.05), and H
2
S increased significantly (
P
<
0.01). The improvement degree of the NYHA cardiac function classification in the treatment group was higher than that in the control group, but there was no significant difference.
Conclusion
2
Shenqi Yangxin decoction is effective in treating ICM patients with Qi and Yin deficiency and blood stasis, which could significantly improve cardiac function and quality of life, and its therapeutic effect may be related to the regulation of serum H
2
S and Ca
2+
levels.
中华医学会心血管病学分会 , 中华心血管病杂志编辑委员会 . 缺血性心肌病血运重建专家共识 [J]. 中华心血管病杂志 , 2025 , 53 ( 4 ): 343 - 355 .
Chinese Society of Cardiology Chinese Medical Association , Editorial Board of Chinese Journal of Cardiology . Expert consensus on revascularization in ischemic cardiomyopathy [J]. Chin J Cardiol , 2025 , 53 ( 4 ): 343 - 355 .
PASTENA P , FRYE J T , HO C , et al . Ischemic cardiomyopathy:Epidemiology,pathophysiology,outcomes,and therapeutic options [J]. Heart Fail Rev , 2024 , 29 ( 1 ): 287 - 299 .
ZHANG Z H , MENG F Q , HOU X F , et al . Clinical characteristics and long-term prognosis of ischemic and non-ischemic cardiomyopathy [J]. Indian Heart J , 2020 , 72 ( 2 ): 93 - 100 .
BRAUNWALD E . Heart failure [J]. JACC Heart Fail , 2013 , 1 ( 1 ): 1 - 20 .
陈牧雷 , 董蔚 , 李广平 , 等 . 针对晚期心力衰竭患者应规范使用正性肌力药物——《欧洲心脏病学会心力衰竭协会临床专家共识》解读 [J]. 中国循环杂志 , 2023 , 38 ( 8 ): 882 - 886 .
CHEN M L , DONG W , LI G P , et al . Interpretation of Inotropic therapy in patients with advanced heart failure:A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology [J]. Chin Cire J , 2023 , 38 ( 8 ): 882 - 886 .
中华医学会心血管病学分会 , 中国医师协会心血管内科医师分会 , 中国医师协会心力衰竭专业委员会 , 等 . 中国心力衰竭诊断和治疗指南2024 [J]. 中华心血管病杂志 , 2024 , 52 ( 3 ): 235 - 275 .
Chinese Society of Cardiology Chinese Medical Association , Chinese College of Cardiovascular Physician , Chinese Heart Failure Association of Chinese Medical Doctor Association , et al . Chinese guidelines for the diagnosis and treatment of heart failure 2024 [J]. Chin J Cardiol , 2024 , 52 ( 3 ): 235 - 275 .
候中豪 , 贾炜豪 , 闫中敏 , 等 . 基于气血络脉心体系探讨缺血性心肌病心力衰竭 [J]. 中国医药导报 , 2024 , 21 ( 19 ): 140 - 144 .
HOU Z H , JIA W H , YAN Z M , et al . Study on ischemic cardiomyopathy and heart failure based on system of Qi,blood collaterals and heart [J]. Chin Med Rep , 2024 , 21 ( 19 ): 140 - 144 .
陆曙 . 陆曙效方治验——参芪养心汤 [J]. 江苏中医药 , 2022 , 54 ( 1 ): 14 - 15 .
LU S . LU Shu's experience of effective prescriptions:Shenqi Yangxin decoction [J]. Jiangsu J Tradit Chin Med , 2022 , 54 ( 1 ): 14 - 15 .
魏靖恒 , 石晓路 , 杨威 , 等 . 生脉散调控气阴两虚型心律失常的心脏重构机制探析 [J]. 中国实验方剂学杂志 , 2024 , 30 ( 4 ): 248 - 259 .
WEI J S , SHI X L , YANG W , et al . Mechanism of Shengmaisan regulating cardiac remodeling of arrhythmias with deficiency of qi and yin [J]. Chin J Exp Tradit Med Form , 2024 , 30 ( 4 ): 248 - 259 .
陆曙 , 张寄南 , 杨笛 , 等 . 黄芪总皂甙影响病毒感染心肌细胞肌浆网钙泵活力及其基因表达 [J]. 中华医学杂志 , 2000 , 80 ( 12 ): 953 - 954 .
LU S , ZHANG J N , YANG D , et al . Astragaloside affects the activity of calcium pumps in the sarcoplasmic reticulum of cardiomyocytes infected by viruses and their gene expression [J]. Chin Med J , 2000 , 80 ( 12 ): 953 - 954 .
张帅 , 林建秀 , 张卓珺 , 等 . 缺血性心肌病的关键基因鉴定及中药预测 [J]. 湖南中医杂志 , 2024 , 40 ( 10 ): 139 - 151 .
ZHANG S , LIN J X , ZHANG Z Z , et al . Identification of key genes and prediction of traditional Chinese medicine drugs for ischemic cardiomyopathy [J]. Hunan J Tradit Chin Med , 2024 , 40 ( 10 ): 139 - 151 .
SHAO M J , ZHUO C J , JIANG R H , et al . Protective effect of hydrogen sulphide against myocardial hypertrophy in mice [J]. Oncotarget , 2017 , 8 ( 14 ): 22344 - 22352 .
KING A L , POLHEMUS D J , BHUSHAN S , et al . Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent [J]. Proc Natl Acad Sci USA , 2014 , 111 ( 8 ): 3182 - 3187 .
WATTS M , KOLLURU G K , DHERANGE P , et al . Decreased bioavailability of hydrogen sulfide links vascular endothelium and atrial remodeling in atrial fibrillation [J]. Redox Biol , 2021 , 38 : 101817 .
中华中医药学会 . 中医内科临床诊疗指南 [M]. 北京 : 中国中医药出版社 , 2019 .
China Association of Chinese Medicine . Clinical guidelines for diagnosis and treatment of internal diseases in TCM [M]. Beijing : China Press of Chinese Medicine , 2019 .
郑筱萸 . 中药新药临床研究指导原则 [M]. 北京 : 中国医药科技出版社 , 2002 .
ZHENG X Y . Guiding Principles for Clinical Research of New Traditional Chinese Medicine [M]. China Medical Science and Technology Press , 2002 .
Committee for Medicinal Products for Human Use EMA . Guideline on clinical trials in small populations [EB/OL]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-trials-small-populations_en.pdf https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-trials-small-populations_en.pdf .
孙梓宜 , 姚魁武 , 王子涵 , 等 . 升解通瘀汤对缺血性心肌病致慢性心力衰竭气虚血瘀证患者尿液代谢组学的影响 [J]. 中医杂志 , 2023 , 64 ( 7 ): 692 - 701 .
SUN Z Y , YAO K W , WANG Z H , et al . Effect of Shengjie Tongyu decoction on urine metabolomics in patients with ischemic cardiomyopathy-induced chronic heart failure and Qi deficiency and blood stasis syndrome [J]. J Tradit Chin Med , 2023 , 64 ( 7 ): 692 - 701 .
黎鹏程 , 卢丽丽 , 胡秀清 , 等 . 基于“血不利则为水”论治冠心病心力衰竭 [J]. 中华中医药杂志 , 2020 , 35 ( 4 ): 1872 - 1875 .
LI P C , LU L L , HU X Q , et al . Treatment of heart failure caused by coronary heart disease based on the theory of "unsmooth blood circulation results in water retention" [J]. China J Tradit Chin Med Pharm , 2020 , 35 ( 4 ): 1872 - 1875 .
KOLLURU G K , SHACKELFORD R E , SHEN X , et al . Sulfide regulation of cardiovascular function in health and disease [J]. Nat Rev Cardiol , 2023 , 20 ( 2 ): 109 - 125 .
MEDINA-TEROL G J , CHIMAL L , HUERTA DE LA CRUZ S , et al . H 2 S treatment reverts cardiac hypertrophy and increases SERCA2a activity but does not fully restore cardiac Ca 2+ handling in hypertensive rats [J]. Cell Calcium , 2025 , 128 : 103015 .
CAI W J , WANG M J , MOORE P K , et al . The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation [J]. Cardiovasc Res , 2007 , 76 ( 1 ): 29 - 40 .
TIAN D Y , DONG J H , JIN S , et al . Endogenous hydrogen sulfide-mediated MAPK inhibition preserves endothelial function through TXNIP signaling [J]. Free Radic Biol Med , 2017 , 110 : 291 - 299 .
LIU M J , LI Y , LIANG B , et al . Hydrogen sulfide attenuates myocardial fibrosis in diabetic rats through the JAK/STAT signaling pathway [J]. Int J Mol Med , 2018 , 41 ( 4 ): 1867 - 1876 .
陈聪 , 成细华 , 任婷 , 等 . 加味丹参饮作用内源性H 2 S合成途径保护心肌缺血/再灌注损伤的实验研究 [J]. 湖南中医药大学学报 , 2019 , 39 ( 10 ): 1183 - 1188 .
CHEN C , CHENG X H , REN T , et al . Experimental study on effects of Jiawei Danshen decoction on endogenous H 2 S synthesis pathway to protect myocardial ischemia/reperfusion injury [J]. J Hunan Univ Tradit Chin Med , 2019 , 39 ( 10 ): 1183 - 1188 .
江海龙 , 吴宏超 , 李志梁 , 等 . 冠心病患者血浆中新型气体信号分子硫化氢的变化 [J]. 第一军医大学学报 , 2005 , 25 ( 8 ): 951 - 954 .
JIANG H L , WU H C , LI Z L , et al . Changes of the new gaseous transmitter HS in patients with coronary heart disease [J]. Acad J First Med Coll PLA , 2005 , 25 ( 8 ): 951 - 954 .
POLHEMUS D J , CALVERT J W , BUTLER J , et al . The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure [J]. Scientifica (Cairo) , 2014 , 2014 : 768607 .
SUN Y G , CAO Y X , WANG W W , et al . Hydrogen sulphide is an inhibitor of L -type calcium channels and mechanical contraction in rat cardiomyocytes [J]. Cardiovasc Res , 2008 , 79 ( 4 ): 632 - 641 .
REDEL-TRAUB G , MARX S O , MARKS A R . Targeting calcium regulation for heart failure and arrhythmia therapeutics:A critical review [J]. Circulation , 2025 , 152 ( 13 ): 957 - 970 .
BAI X P , IHARA E , HIRANO K , et al . Endogenous hydrogen sulfide contributes to tone generation in porcine lower esophageal sphincter via Na + /Ca 2+ exchanger [J]. Cell Mol Gastroenterol Hepatol , 2017 , 5 ( 3 ): 209 - 221 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
